Camptothecin (CPT) is an antitumor alkaloid isolated from Camptotheca acuminata, a tree native to southern China. Although this compound showed strong activity against experimental tumor models, it was found to be ineffective in clinical studies. [1] [2] [3] Severe side effects included myelosuppression, vomiting, diarrhea, and hemorrhagic cystitis, and as a result clinical trials were discontinued. 4, 5) Many derivatives of CPT that have less toxicity and higher solubility in water have been synthesized and evaluated. CPT-11, a water-soluble analog of CPT, has broad-spectrum activity against murine tumors and human tumor xenografts, including multidrug-resistant tumors. [6] [7] [8] A recent study showed that a half-molecule ABC transporter BCRP/MXR/ABCP is involved in CPT-11 resistance. 9) Glucuronidation of SN-38, an active metabolite of CPT-11, by UDP-glucuronosyltransferase is another important determinant for CPT-11 sensitivity. 10) Clinical studies demonstrated that CPT-11 is effective against various types of cancer. [11] [12] [13] [14] A survival advantage of CPT-11 treatment was found especially for colon cancer. 14) CPT inhibits both DNA and RNA synthesis 15, 16) and induces reversible DNA strand breaks in mammalian cells, 17) due to the inhibition of DNA topoisomerase I (topo I). 18, 19) Eukaryotic DNA topoisomerases are involved in balancing torsional stress arising in DNA during transcriptional and replicational processes. 20) Topo I resolves torsional problems by a mechanism that involves concerted breaking and rejoining of DNA along with strand passage. CPT binds to topo I in the enzyme-DNA complex and thereby inhibits the religation reaction of the enzyme. 18, 21) Crystal structures of human topo I have been reported, and a mode of CPT binding to the enzyme-DNA complex was proposed based on the structural information. 22) One possible mechanism of CPT-induced cell killing is that the drug-stabilized cleavage complex interferes with replication forks, resulting in replication arrest and fork disassembly. 23, 24) To examine the role of topo I in the mechanism of CPT action and to characterize the resistance mechanism to 4 To whom correspondence and reprint requests should be addressed.
E 25) In previous studies, we demonstrated the quantitative decrease in the cellular content of topo I in three CPT-resistant lines, HT-29/CPT, St-4/CPT and P388/CPT from the human colon cancer cell line HT-29, the human stomach cancer cell line St-4 and the mouse leukemia cell line P388, respectively. 25) In this study, we show that two species of TOP1 mRNA, the wild-type (4.0 kb) and a deleted-type (3.3 kb), are expressed in HT-29/ CPT. Possible involvement of the expression of the deleted TOP1 mRNA in CPT resistance was examined by means of DNA transfection experiments.
MATERIALS AND METHODS
Cell culture and assay of drug sensitivity Two CPTresistant sublines HT-29/CPT and St-4/CPT were established from human colon cancer cell line HT-29 and human stomach cancer cell line St-4, respectively, by treating the tumor cells in vitro with increasing concentrations of CPT. 25) Cells were grown in DMEM supplemented with 10% fetal bovine serum. The sensitivities of the cultured cell lines to drugs were evaluated in terms of the inhibition of cell growth after incubation at 37°C for 5 days with various concentrations of drugs, as described previously.
26) The number of tumor cells was counted in a Coulter counter, and the IC 50 values were determined. Immunoblot analysis Cells were solubilized with 2% SDS, 5% 2-mercaptoethanol, and 50 mM Tris-HCl, pH 7.5. The cell lysates (1×10 5 cells equivalent) were subjected to electrophoresis on 5-20% SDS-polyacrylamide gels. 27) After electrophoresis, the protein was transferred onto a nitrocellulose membrane. For the detection of topo I, the blot was incubated with the anti-topo I monoclonal antibody T14C, 25) washed, and then reacted with 125 Ilabeled anti-mouse IgG (Amersham, Arlington Heights, IL). For the detection of exogenous topo I with the HAtag, the blot was incubated with the anti-HA polyclonal antibody Y-11 (Santa Cruz Biotechnology, Santa Cruz, CA), washed, and reacted with peroxidase-conjugated anti-rabbit IgG (Amersham). The membrane-bound peroxidase was visualized using an ECL+Plus kit (Amersham). RNA blot analysis A TOP1 cDNA clone λhTOP1-D2 was kindly provided by Dr. L. F. Liu. 28) Total cellular RNA was extracted after disruption of tumor cells in guanidine thiocyanate solution followed by CsCl density gradient centrifugation. Polyadenylated mRNA was obtained by chromatography on oligodeoxythymidylate cellulose. The mRNA samples (5 µg/lane) were subjected to electrophoresis on a 1% formaldehyde-agarose gel and transferred to a nitrocellulose membrane. The TOP1 cDNA probe was radiolabeled with [α-32 P]dCTP (3000 Ci/mmol, Amersham), and hybridization was carried out as described previously.
29) The membrane filter was then washed and subjected to autoradiography. The equality of the mRNA loading in each lane of the blot was confirmed by control hybridization with a human β-actin cDNA probe, as described.
30)
Isolation of cDNA clones and construction of expression vectors The TOP1 clones corresponding to 4.0-kb and 3.3-kb TOP1 mRNAs were isolated from an HT-29/ CPT cDNA library in λgt11 31) using the TOP1 cDNA clone λhTOP1-D2 as a probe. Nucleotide sequences of the wild-type (4.0 kb) and the deleted (3.3 kb) TOP1 cDNA were confirmed by an ABI PRISM 377 DNA Sequencing System (Perkin-Elmer, Foster City, CA). Next, the HAtag 32) was added upstream from the first ATG codon of the wild-type or the deleted TOP1 cDNA to differentiate between the endogenous and exogenous topo I in the transfected cells. For this purpose, the 5′-parts of the wildtype and the deleted TOP1 cDNAs were amplified by PCR using 5HA-S (5′-CGCGCTAGCATGTACCCATACGAC-GTCCCAGACTACGCTATGAGTGGGGACCACCTCCA C-3′; HA-antigen sequence and nucleotides 1 to 22 from the first ATG of TOP1 cDNA 33) ) and 5HA-AS (5′-CAT-GATTCGTCTCTTCAGCATGCCCATCTTG-3′; antisense of nucleotides 1104 to 1134 of TOP1 cDNA) as primers. The resulting PCR products were ligated with the 3′-part of TOP1 cDNA. The wild-type and the deleted TOP1 cDNAs with the HA-tag were cloned into a mammalian expression vector, pCALNLw, that has a strong CAG promoter to drive the expression of the cDNA. 34) Nucleotide sequences of these constructs were confirmed. Transfection Mouse fibroblast NIH3T3 cells (5×10 5 cells/60-mm dish) were cotransfected with the expression construct containing the TOP1 cDNA (5 µg) and a neomycin-resistant plasmid pMC1neopolyA (0.25 µg; Stratagene, La Jolla, CA) using the SuperFect Transfection Reagent (QIAGEN, Valencia, CA). The cells were replated 2 days after transfection and selected in medium containing 600 µg/ml of G418. G418-resistant colonies were isolated and used in further studies. Integration of the TOP1 cDNA in the transfectants was examined by genomic PCR using a sense-strand primer p1 (5′-TAC-GACGTCCCAGACT-3′; the sequence in the HA-tag) and an antisense-strand primer p2 (5′-CAGGAGGCTCTA-TCTT-3′; antisense of nucleotides 1060 to 1075 of TOP1 cDNA). Expression of the exogenous TOP1 mRNA in the transfectants was examined by RT-PCR using a sense-strand primer p1 and an antisense-strand primer p3 (5′-AGAACTCTGCCTCTTG-3′; antisense of nucleotides 2306 to 2321 of TOP1 cDNA). As an internal standard of RT-PCR, β 2 -microglobulin mRNA in the transfectants was amplified using a sense-strand primer (5′-ACCCCCACT-GAAAAAGATGA-3′) and an antisense-strand primer (5′-ATATTCAAACCTCCATGATG-3′). In vitro transcription/translation To examine the topo I activity of the truncated enzyme, the wild-type and the deleted TOP1 cDNAs were cloned into a pGEM-4 vector (Promega, Madison, WI) with an SP6 promoter, and the respective topo I proteins were synthesized using in vitro transcription/translation systems (Promega). 35, 36) Topo I activity was assayed essentially as described by Ishii et al. 37) In brief, the activity was measured by relaxing the supercoiled plasmid DNA at 37°C for 15 min in a 20 µl reaction mixture containing 0.2 µg of supercoiled pT2GN plasmid DNA, 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA, 0.5 mM dithiothreitol, 30 mg/ml BSA, 10% glycerol and various concentrations of in vitro translation products. The reaction was terminated by adding SDS to 1%. The extent of DNA relaxation was evaluated after electrophoresis on 0.8% agarose gels.
RESULTS
Expression of TOP1 mRNA in HT-29/CPT and St-4/ CPT Degrees of resistance of these CPT-resistant lines to inhibitors of topo I and II are summarized in Table I . HT-29/CPT and St-4/CPT expressed approximately oneeighth the amount of topo I as did the corresponding parental lines (Fig. 1A) . To understand the molecular basis of this lowered expression in the CPT-resistant cells, RNA blot analysis was carried out using the human TOP1 cDNA probe λhTOP1-D2. As shown in Fig. 1B , two species of the TOP1 mRNA were found in HT-29/CPT. The longer mRNA (4.0 kb) is the wild-type TOP1 mRNA, and the shorter mRNA (3.3 kb) appears to possess a deletion. The amounts of the two mRNAs in HT-29/CPT were approximately one-half the amount of the wild-type mRNA expressed in the parental HT-29. On the other hand, St-4/CPT expressed only the wild-type TOP1 mRNA, and at a lower level than in St-4 (Fig. 1B) . Identification of the deleted region in the 3.3-kb mRNA To identify the deleted region of the 3.3-kb mRNA expressed in HT-29/CPT, we carried out a series of gene amplification experiments using various primers with cDNA templates from HT-29 and HT-29/CPT. One set of primers, 2F (5′-TCCCAGATCGAAGCGGATTT-3′; nucleotides 28 to 47 from the first ATG of TOP1 cDNA 33) ) and 5R (5′-GATTCGTCTCTTCAGCATGC-3′; antisense of nucleotides 1112 to 1131) successfully amplified the deleted cDNA fragment in HT-29/CPT (data not shown). The expected size of the PCR fragment was 1104 bp; however, the amplification gave rise to a 432-bp fragment in HT-29/CPT. The difference between the lengths of the PCR fragment and the expected fragment, 0.7 kb, was the same as the difference between the lengths of the two TOP1 mRNAs expressed in HT-29/CPT (Fig. 1B) . The 432-bp PCR fragment was subcloned into SmaI-digested pUC13 vector and sequenced. The nucleotide sequence of the PCR fragment was identical to the reported sequence of TOP1 cDNA 33) but lacked 672 bp (nucleotides 58-729 or 59-730). This deletion should cause an in-frame deletion of amino acids 20-243 of human topo I (Fig. 2) . Since the nucleotides at 58 and 730 are both G, we cannot identify which was deleted. However, it is likely that the region 59-730 was deleted because it is identical to exons 3-9 of the human TOP1 gene.
38) Therefore, we refer to the short mRNA as exon 3-9-deleted TOP1 mRNA. In spite of the expression of the truncated mRNA with an in-frame deletion in HT-29/CPT, we could not detect the corresponding 70-kDa protein by western blots with anti-topo I monoclonal antibody T14C (Fig. 1A) or anti-topo I polyclonal antibody Scl-70 (Topogen, Columbus, OH) (data not shown).
Mammalian expression experiments
The wild-type and the deleted TOP1 cDNAs were cloned into a pCALNLw vector and were termed pCAL-TW and pCAL-TD, respectively. Mouse fibroblast NIH3T3 cells were cotransfected with pCAL-derived construct and pMC1neopolyA. The transfectants were selected in medium containing 600 µg/ ml of G418. G418-resistant colonies were isolated and used in further studies.
Integration of the TOP1 cDNA and the expression of the exogenous TOP1 mRNA in the transfectant cells were examined in a series of PCR experiments. The position of PCR primers and the expected sizes of amplified products are summarized in Fig. 3A . In this series, only the exogenous TOP1 cDNA and mRNA were amplified since primer p1 codes the HA-tag. First, integration of the exogenous TOP1 cDNA with the HA-tag was examined by genomic PCR using primers p1 and p2. Transfectant clones with integration of the exogenous TOP1 cDNA (three clones, W2, W4 and W5, transfected with the wild- type TOP1 cDNA and five clones, D1, D2, D3, D4 and D5, transfected with the deleted TOP1 cDNA) were used in further experiments (Fig. 3B) . Integration of the exogenous full-length TOP1 cDNA in these clones were confirmed by another genomic PCR using primers p1 and p3 (data not shown). As shown in Fig. 3C , expression of the exogenous, wild-type TOP1 mRNA (2.3 kb) was detected in W2, W4 and W5 by RT-PCR using the p1 and p3 primers. Expression of the deleted TOP1 mRNA (1.6 kb) was detected in D1, D2 and D3, but not in D4 and D5.
Western blot analysis using anti-HA antibody revealed high-level expressions of the exogenous topo I in all three clones transfected with the wild-type TOP1 cDNA (Fig.  4) . No exogenous protein with the expected size was found in clones transfected with the deleted TOP1 cDNA (Fig. 4) . CPT sensitivity of transfected clones The sensitivity to CPT of the transfectants was examined using a cell growth inhibition assay (Fig. 5) . The mock transfectant clones n1, n2, n3 and n4 showed similar CPT sensitivity to the parental 3T3 cells (IC 50 values were 4.6-5.5 ng/ml) (Fig. 5A) . The IC 50 values to CPT of W2, W4 and W5 were 2.1, 1.6 and 1.3 ng/ml, respectively, which were approximately 3-fold higher than that of the control cells (Fig. 5B) . The IC 50 values to CPT of D1, D2, D3, D4 and D5 were 4.3 to 6.3 ng/ml, which showed no significant changes in drug resistance from that of the control cells (Fig. 5C ). The IC 50 values of these clones are plotted in Fig. 6 . In vitro transcription/translation of topo I To examine the catalytic activity of the deleted topo I, in vitro translation experiments were carried out using pGEM-TW or pGEM-TD with the HA-tagged wild-type or deleted TOP1 cDNA, respectively. High-level expression of the wildtype topo I (100-kDa protein) was detected by western blot analysis. The deleted topo I protein (70 kDa) was also detected, but its expression level was much lower than that of the wild-type protein (Fig. 7A) . The 100-kDa protein showed in vitro DNA relaxation activity, whereas the 70-kDa protein had no detectable activity (Fig. 7B ).
DISCUSSION
In this study, we showed the expression of two species of TOP1 mRNA in HT-29/CPT cells. The longer mRNA (4.0 kb) was the wild-type TOP1 mRNA, and the shorter mRNA (3.3 kb) had a deletion that resulted in the internal deletion of 224 amino acids (residues 20-243) of human topo I. The cDNAs corresponding to both mRNAs were isolated and introduced into NIH3T3 cells. Cells transfected with the wild-type TOP1 cDNA showed higher sensitivity to CPT than did 3T3 cells. On the other hand, transfectant clones with the deleted TOP1 cDNA showed similar levels of drug resistance to 3T3 cells.
The amounts of the wild-type and mutant mRNAs in HT-29/CPT were the same and together were approximately one-half the amount of wild-type mRNA expressed in the parental HT-29 (Fig. 1B) . This suggested that the deleted TOP1 mRNA in HT-29/CPT cells was transcribed from one of the alleles of the genome. To identify the possible deletion or rearrangement in one of the alleles of the TOP1 gene, Southern blot analysis was carried out using eight restriction endonucleases. However, we could not identify significant rearrangements or deletions of the TOP1 gene in HT-29/CPT (data not shown). Therefore, it is likely that certain mutations in the splicing donor/ acceptor sites in one of the alleles in HT-29/CPT resulted in a 672-bp deletion of the TOP1 mRNA. Isolation and analysis of the genomic DNA of HT-29/CPT is ongoing to clarify this point.
In this study we show the expression of truncated TOP1 mRNA as a mechanism of CPT resistance. Expression of shorter mRNA was reported by Matsumoto et al. as a mechanism of resistance to topo II inhibitor. 39) They reported that an acquired 600-bp deletion in one topo IIα allele resulted in a reduced topo IIα protein level of a VP-16-resistant subline MDA-MB-231-VP7. Therefore expression of shorter mRNA may be an infrequent event, but it can happen in other systems.
Quantitative reduction of topo I in resistant cells has been reported in various systems and seems to be the most common mechanism of CPT resistance. Any mechanism which would result in lowered protein expression can be related to CPT resistance. Such mechanisms include low mRNA expression, genomic deletion, alternative splicing, protein instability, and so on. We previously reported the reduction of cellular topo I content in HT-29/CPT, St-4/ CPT and P388/CPT. 25) In this study, we found that the expression of TOP1 mRNA was also decreased in St-4/ CPT from the parental St-4. These results suggest that the decrease in the cellular content of topo I in St-4/CPT was caused simply by the reduction in the cellular content of its mRNA. In contrast, the total amount of TOP1 mRNA in HT-29/CPT appeared similar to the mRNA expressed in the parental HT-29, suggesting that mechanisms related to the transcription efficiency and mRNA stability were not altered in HT-29/CPT. The amount of wild-type TOP1 mRNA expressed in HT-29/CPT cells was approximately one-half that in parental HT-29; however, the cellular content of topo I in HT-29/CPT was eight-fold less than that in the parental HT-29. Therefore, the expression level of wild-type TOP1 mRNA in HT-29/CPT does not account for the low amount of the protein. This result suggests that there exists a mechanism other than lowered mRNA expression for the low-level content of topo I in HT-29/ CPT. One possible mechanism is an acceleration of topo I degradation in HT-29/CPT. The stability of topo I protein and proteasome function in HT-29/CPT is to be examined to clarify this point.
NIH3T3 cells transfected with the wild-type TOP1 cDNA showed higher sensitivity to CPT than the control cells (Figs. 5, 6 ). TOP1-transfected baby hamster kidney cells expressed two-to five-fold higher amounts of wildtype topo I and showed increased cell death in the presence of CPT. 40) In another system, COS cells expressing Saccharomyces cerevisiae topo I showed increased CPT sensitivity. 41 ) These results clearly demonstrate that cellular contents of topo I directly correlate to the sensitivity of cells to CPT.
Mechanisms of CPT resistance other than the quantitative reduction of topo I have been reported in various experimental systems. We previously reported the expression of mutant topo I in a CPT-resistant human T lymphoblastic leukemia cell line, CPT-K5. 42) An amino acid change from Asp to Gly at residue 533 is responsible for the CPT resistance of the enzyme. 43, 44) The expression of mutant (Gly-533) topo I confers a dominant form of CPT resistance in cells expressing wild-type topo I. 45) Maliepaard et al. recently reported that a half-molecule ABC transporter BCRP/MXR/ABCP is involved in CPT-11 resistance.
9) Glucuronidation of SN-38, an active metabolite of CPT-11, by UDP-glucuronosyltransferase is another important determinant for CPT-11 sensitivity. 10) The exon 3-9-deleted topo I of HT-29/CPT lacks amino acid residues 20-243. The deleted region contains the putative nuclear localization signal (residues 141-210). 46) Human topo I with the deletion of the 70-aminoacid region showed topo I catalytic activity in vitro. Overexpression of topo I in S. cerevisiae is lethal, whereas overexpression of the topo I with the deletion of the 70-amino-acid region did not result in cell death, 46) suggesting that the truncated enzyme is inactive in vivo because of a defect in its transport into the nucleus. Therefore, it is not surprising that the CPT sensitivity of the NIH3T3 cells was not affected by the transfection of the deleted TOP1 cDNA. It is possible to speculate that the exon 3-9-deleted topo I is unstable when it exists in the cytoplasm. In in vitro translation experiments, expression of a 70-kDa protein was detected from the deleted TOP1 cDNA. But, as shown in Fig. 7A , the level of the 70-kDa protein was much lower than that of the 100-kDa protein from the wild-type TOP1 cDNA. The inefficient expression of the 70-kDa protein supports the notion that the 3-9-exon region of TOP1 gene is involved in the enzyme's stability. This may be the reason why we could not detect the 70-kDa protein expression in HT-29/CPT or in cells transfected with the deleted TOP1 cDNA.
Whether or not the exon 3-9-deleted topo I encodes a functional enzyme was not clarified in this study. Vaccinia virus topo I consists of 314 amino acids and has a molecular weight of 32000, which is one-third of the molecular weight of the human enzyme. 47) In addition, the vaccinia virus enzyme does not have the region that corresponds to exons 3-9 of the human enzyme. Therefore, it is possible that the exon 3-9-deleted topo I does, in fact, function. However, DNA relaxation activity of the 70-kDa protein synthesized by in vitro translation could not be detected, probably due to the low expression of the protein (Fig.  7B ). Large-scale preparation and purification of the 70-kDa protein will be necessary to elucidate this point.
In this study, we identified the exon 3-9-deleted TOP1 mRNA in CPT-resistant cells. Cells transfected with the deleted TOP1 cDNA showed no significant changes in CPT sensitivity, probably because of the instability of the truncated topo I protein in the cells. These results suggest that expression of the deleted TOP1 mRNA leads to low expression of CPT-sensitive topo I in resistant cells. Possible interactions of the truncated topo I with wild-type enzyme and endogenous topo I-interacting proteins could be examined more precisely by means of a double transfection experiment with both the deleted and wild-type TOP1.
